Clinical Trial Update: Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating an Anti-CLL1-CD33-NKG2D bicephali CAR-T therapy for relapsed/refractory acute myeloid leukemia is listed as not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Anti-CLL1-CD33-NKG2D bicephali CAR-T

Snippet

Sponsor: Xuzhou Medical University | Conditions: AML (Acute Myeloid Leukemia) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING